Effectiveness of <scp>COVID</scp>‐19 vaccine boosters for reducing <scp>COVID</scp>‐19 mortality among people aged 65 years or older, Australia, August 2023 – February 2024: a retrospective observational cohort study
Recent booster vaccination with the XBB.1.5 monovalent COVID-19 vaccine was highly effective for preventing COVID-19 deaths among people aged 65 years or older, including during the period in which the JN.1 was the dominant SARS-CoV-2 Omicron subvariant. Our findings provide support for the recommendation that people aged 65 years or older receive COVID-19 vaccine booster doses every six months.
Authors
- Bette Liu (ORCID: https://orcid.org/0000-0002-0787-5825)
- Sandrine Stepien (ORCID: https://orcid.org/0000-0002-6561-7496)
- Anish Scaria (ORCID: https://orcid.org/0000-0002-5678-6677)
- Kristine Macartney (ORCID: https://orcid.org/0000-0002-4675-0232)
Institutions
- The University of Sydney (AU)
- UNSW Sydney (AU)
- National Centre for Immunisation Research & Surveillance (AU)
Publication Details
- Journal
- The Medical Journal of Australia
- Published
- 2025-07-24
- DOI
- https://doi.org/10.5694/mja2.70015
- Citations
- 1
- Primary Topic
- Chronic Disease Management Strategies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- GAVI Alliance
- World Health Organization
- Wellcome Trust
- University of New South Wales
- Medical Research Council
- National Health and Medical Research Council